Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm

Cui, Ming; Hu, Ya; Zhang, Zejian; Chen, Tianqi; Dai, Menghua; Xu, Qiang; Guo, Junchao; Zhang, Tai**; Liao, Quan; Yu, Jun; Zhao, Yupei

doi:10.1038/s41392-023-01645-8

Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm

Article
Open access
Published: 18 October 2023

Volume 8, article number 406, (2023)
Cite this article

Download PDF

You have full access to this open access article

Signal Transduction and Targeted Therapy

Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm

Download PDF

Ming Cui ORCID: orcid.org/0000-0001-8770-4585¹^na1,
Ya Hu¹^na1,
Zejian Zhang²,
Tianqi Chen²,
Menghua Dai¹,
Qiang Xu¹,
Junchao Guo¹,
Tai** Zhang¹,
Quan Liao¹,
Jun Yu^3,4 &
…
Yupei Zhao ORCID: orcid.org/0000-0001-7081-2299¹

2254 Accesses
7 Altmetric
1 Mention
Explore all metrics

Abstract

Pancreatic cystic neoplasms (PCNs) are recognized as precursor lesions of pancreatic cancer, with a marked increase in prevalence. Early detection of malignant PCNs is crucial for improving prognosis; however, current diagnostic methods are insufficient for accurately identifying malignant PCNs. Here, we utilized mass spectrometry (MS)-based glycosite- and glycoform-specific glycoproteomics, combined with proteomics, to explore potential cyst fluid diagnostic biomarkers for PCN. The glycoproteomic and proteomic landscape of pancreatic cyst fluid samples from PCN patients was comprehensively investigated, and its characteristics during the malignant transformation of PCN were analyzed. Under the criteria of screening specific cyst fluid biomarkers for the diagnosis of PCN, a group of cyst fluid glycoprotein biomarkers was identified. Through parallel reaction monitoring (PRM)-based targeted glycoproteomic analysis, we validated these chosen glycoprotein biomarkers in a second cohort, ultimately confirming N-glycosylated PHKB (Asn-935, H5N2F0S0; Asn-935, H4N4F0S0; Asn-935, H5N4F0S0), CEACAM5 (Asn-197, H5N4F0S0) and ATP6V0A4 (Asn-367, H6N4F0S0) as promising diagnostic biomarkers for distinguishing malignant PCNs. These glycoprotein biomarkers exhibited robust performance, with an area under the curve ranging from 0.771 to 0.948. In conclusion, we successfully established and conducted MS-based glycoproteomic analysis to identify novel cyst fluid glycoprotein biomarkers for PCN. These findings hold significant clinical implications, providing valuable insights for PCN decision-making, and potentially offering therapeutic targets for PCN treatment.

Quantitative proteomic analysis of pancreatic cyst fluid proteins associated with malignancy in intraductal papillary mucinous neoplasms

Article Open access 18 April 2018

Integrated targeted metabolomic and lipidomic analysis: A novel approach to classifying early cystic precursors to invasive pancreatic cancer

Article Open access 15 July 2019

Molecular Diagnosis of Cystic Neoplasms of the Pancreas: a Review

Article 03 March 2020

Introduction

The detection of pancreatic cystic neoplasm (PCN) has markedly increased due to more frequent applications of cross-sectional imaging, leading to a challenging dilemma in diagnosis and treatment. It is estimated that PCNs are present in more than 40% of individuals aged 60 years and older, and thus have become a significant global disease burden.^1,2 A diverse group of lesions, such as intraductal papillary mucinous neoplasm (IPMN), mucinous cystic neoplasm (MCN), serous cystic neoplasm (SCN), and others, constitute PCNs, encompassing a range of conditions from benign to malignant. The majority of PCNs exhibit indolent behavior, characterized by slow progression and low malignant potential. Only a small subset of PCNs can give rise to pancreatic cancer, mainly composed of high-grade and invasive IPMNs and MCNs.³ The identification of indolent PCNs could prevent unnecessary pancreatectomy, which is associated with a considerable rate of postoperative complications and increased medical costs.⁴ Conversely, the early detection of malignant PCNs enables timely management of pancreatic cancer and substantially improves prognosis.⁵ Thus, the accurate differentiation of malignant PCNs from other indolent lesions is continually highlighted.

Several international guidelines have been established and have improved the clinical management of PCN.^6,7,8 However, recent studies have shown that risk stratification based on conventional clinical and radiological factors remains unsatisfactory.^9,10 The primary concern lies in the relatively high proportion of benign PCN patients undergoing surgery following the current guidelines, highlighting the pressing need to enhance diagnostic efficacy and achieve greater specificity in detecting malignant PCNs.

Cyst fluid, primarily produced by neoplastic epithelial cells with PCN, offers a direct way to assess the biological characteristics of these neoplasms. Consequently, cyst fluid analysis has emerged as a crucial approach in assisting the molecular-based risk stratification of PCNs.^11,12 There have been advances in cyst fluid analysis of PCN, particularly in the detection of genomic variants.^13,14 However, the exploration of additional types of cyst fluid biomarkers is still in its nascent stage. Glycosylation is a prevalent posttranslational protein modification. Through glycosylation, a wide range of glycan structures are conjugated to proteins or lipids, forming glycoconjugates that participate in recognition and interaction between cells and their extracellular environment. Recently, alterations in protein glycosylation have been found to be involved in fundamental molecular and cellular processes of carcinogenesis, and thus added as a new hallmark of cancer.^15,16 The identification of cancer-specific glycoproteins holds great potential for the development of novel diagnostic biomarkers with high accuracy. In the past, the complexity of protein glycosylation posed a challenge in simultaneously analyzing all relevant features of glycoproteins, including glyosites, glycoforms, and glycopeptides. With the advent of mass spectrometry (MS) in analyzing intact glycopeptides, high-throughput quantitative detection of both glycosite- and glycoform-specific glycoproteins has become possible.^{17,18,Full size image}

Identification of potential cyst fluid glycoproteins as novel biomarkers in distinguishing malignant PCNs

We further incorporated SCN and LG-IPMN cases as benign PCN group, classified inv-IPMN cases as malignant PCN group, and implemented more strict criteria to screen cyst fluid biomarkers of clinical utility in distinguishing malignancies. Only candidates that were specifically detected in more than 4 cases of one group and not detected in any cases of the other group were retained. Among 642 differentially expressed glycoproteins, four N-glycoproteins with specific glycosites and glycoforms were identified as potential cyst fluid biomarkers that could accurately distinguish malignant PCNs: N-glycosylated ATP6V0A1 (Asn-273, H5N4F0S1), ATP6V0A4 (Asn-367, H6N4F0S0), CEACAM5 (Asn-197, H5N4F0S0) and PHKB (Asn-935, H5N2F0S0, H4N4F0S0 and H5N4F0S0) (Fig. 4a, b). Another three glycoproteins were additionally identified to be exclusively expressed in LG-IPMN: N-glycosylated CELA3B (Asn-114, H5N4F1S0), CEP85 (Asn-646, H6N2F0S0) and TCOF1 (Asn-649, H6N3F1S0) (Fig. 4a, b). Unlike glycoproteins, none of the differentially expressed proteins screened by proteomics between the inv-IPMN group and the LG-IPMN group fulfilled the criteria for ideal biomarkers that would be specifically expressed in inv-IPMN but not in LG-IPMN or SCN. Thus, the above seven glycoproteins, exhibiting specific glycoforms, were identified as potential cyst fluid biomarkers for differentiating PCNs with varying malignant potentials.

Validation of cyst fluid glycoprotein biomarkers in distinguishing malignant PCNs

To validate the above findings, we developed a PRM-based targeted glycoproteomic analysis method and applied it to detect and quantify selected glycoproteins in a second validation cohort. This cohort comprised 30 cyst fluid samples, representing the most common types of PCN (Fig. 5). It included malignant PCNs, such as HG-IPMN, inv-IPMN, and MCN with associated invasive carcinoma. The associated clinical information is provided in Table 1. All selected glycoproteins except for CEP85 were detected by targeted PRM analysis in the validation cohort (Fig. 6a). Notably, N-glycosylated ATP6V0A4 (Asn-367, H6N4F0S0), CEACAM5 (Asn-197, H5N4F0S0) and PHKB (Asn-935, H5N2F0S0; Asn-935, H4N4F0S0; Asn-935, H5N4F0S0) were validated to present high accuracy in distinguishing malignancies (HG-IPMN, inv-IPMN and MCN with associated invasive carcinoma), with sensitivities ranging from 66.7 to 100%, specificities ranging from 81.2% to 93.8%, and area under curve (AUC) values spanning from 0.771 to 0.948 (Fig. 6b, c). Additionally, N-glycosylated TCOF1 (Asn-649, H6N3F1S0) was shown to be a reliable biomarker of low-grade mucinous lesions, and its expression level significantly decreased during malignant transformation (Fig. 6a). N-glycosylated CELA3B (Asn-114, H5N4F1S0) and ATP6V0A1 (Asn-273, H5N4F0S1) were discarded from cyst fluid biomarkers due to their poor discriminative ability shown by PRM analysis.

Discussion

The management of PCNs presents a significant challenge in clinical practice, as accurately distinguishing malignant PCNs based solely on preoperative clinical and radiological features is often difficult. Analyzing the cyst fluid contents of PCN has provided an excellent opportunity to aid in the differential diagnosis of PCN, making the identification of cyst fluid biomarkers for PCN diagnosis an ongoing area of intense research. These methods mainly include cytology examination, genomic variant sequencing, and protein detection.²² For cytology examination, the limited cellular content of cyst fluid and ambiguous interpretation of pathologic grades may impede the sensitivity and accuracy of cytology to distinguish malignant lesions.²³ Therefore, more attention has been given to molecular markers such as nucleic acid or protein biomarkers. Recent studies focusing on cyst fluid nucleic acid markers have propelled this field into a new era.²⁴ DNA/RNA-based next generation sequencing panels, designed based on PCN-related genomic variants such as KRAS, GNAS, TP53, SMAD4, RNF43, PIK3CA, VHL, and CTNNB1, have been validated and proven clinically available, demonstrating optimal diagnostic efficacy.^13,14,25 Compared to nucleic acid markers, the exploration of cyst fluid protein biomarkers remains in a preliminary phase and necessitates further investigation.

In this study, we initially employed MS-based N-glycoproteomic analysis combined with proteomic analysis to comprehensively investigate the glycoproteomic and proteomic signatures of cyst fluid in PCNs. When comparing the differences in glycoprotein and protein profiles between malignant and benign PCNs, our findings revealed that changes in glycoprotein expression exhibited greater discriminative power than those of proteins. This phenomenon aligns with the tumor biology of pancreatic cancer, where specific glycosylation plays a pivotal roles in the process of carcinogenesis.²⁶ Under strict criteria that screen cyst fluid biomarkers specifically detected in malignant PCNs and not detected in benign PCNs, a group of cyst fluid glycoprotein biomarkers has been identified. After validation by PRM-based targeted glycoproteomic analysis in the second cohort, N-glycosylated PHKB (Asn-935, H5N2F0S0; Asn-935, H4N4F0S0; Asn-935, H5N4F0S0), CEACAM5 (Asn-197, H5N4F0S0) and ATP6V0A4 (Asn-367, H6N4F0S0) were confirmed as promising diagnostic biomarkers for distinguishing malignant PCNs and aiding clinical decision-making (Fig. 6d). N-glycosylated PHKB (Asn-935, H5N2F0S0) exhibited the highest AUC value, reaching up to 0.948.

CEACAM5, also known as carcinoembryonic antigen (CEA), is a glycoprotein that is primarily expressed during fetal and placental development, with limited expression in adult tissues and organs, and widely upregulated in a variety of human epithelial malignancies.²⁷ Previous studies have proposed CEA as a cyst fluid marker in diagnosing mucinous cysts, however, its clinical utility is limited by its inability to detect malignancies.²⁸ Recently, glycosylation patterns of CEA were found to be closely associated with cancer progression and could serve as novel biomarkers.^29,30 Our study indicated that the detection of specific glycosylation patterns (Asn-197, H5N4F0S0) could add a novel dimension to CEA and significantly improve its diagnostic capacity to identify malignancies. Phosphorylase kinase β (PHKB) is an enzyme that plays a vital role in glycogen metabolism, particularly in the breakdown (glycogenolysis) of glycogen to produce glucose. ATPase H+ transporting lysosomal accessory protein 4 (ATP6V0A4) is a protein involved in the acidification of intracellular organelles, including lysosomes and endosomes. It serves as a subunit of the vacuolar ATPase (V-ATPase) complex, an ATP-dependent proton pump responsible for acidifying these organelles. In this study, we first introduced N-glycosylated PHKB and ATP6V0A4 as novel biomarkers for malignant PCNs. There are currently limited reports on the roles of PHKB and ATP6V0A4 in carcinogenesis, and there are no studies focusing on their glycosylation at present.^31,32,33 Given the identified association of the aforementioned N-glycoproteins with the malignant transformation of PCN and their potential as novel PCN biomarkers, it is foreseeable that future studies will explore their applicability as novel therapeutic targets for targeted therapy of PCN, particularly in cases involving unresectable or metastatic lesions. To achieve this objective, it is essential to investigate the specific function and mechanisms of N-glycosylated CEA, PHKB, and ATP6V0A4 in PCN carcinogenesis, develop specific monoclonal antibodies or CAR-T/M cells targeting these novel biomarkers, and further examine their therapeutic effects on malignant PCN.

In comparison to previous studies, the cyst fluid glycoprotein biomarkers identified in our study offer some distinct advantages. First, the detection of genomic variants relies on the extraction and enrichment of cell-free DNA (cfDNA), which requires adequate degraded mutant DNA from neoplastic cells and sufficient sampling of pancreatic cyst fluid. Normally, at least one to two milliliters of cyst fluid are needed to extract cfDNA for further sequencing. However, the limited volume of cyst fluid aspirated during EUS, particularly in cases of IPMN containing viscous cyst fluid, poses a challenge for genomic variant detection. In contrast, the detection of glycoproteins can be accomplished with as little as 50 microliters of cyst fluid, given the substantial protein secreted by neoplastic cells into pancreatic cystic fluid. Second, specific glycosylation processes are known to occur selectively in malignancies, leading to the production of unique glycoproteins during carcinogenesis. Therefore, glycoprotein biomarkers hold the potential for higher accuracy compared to protein biomarkers. Our study observed this phenomenon when comparing the proteomic and glycoproteomic results. Notably, the utilization of a single glycoprotein biomarker (N-glycosylated PHKB) achieved a remarkable diagnostic accuracy of over 90%. Based on these observations, we propose that the identified glycoproteins in our study show promise as potential cyst fluid biomarkers. The main limitation of this study is that the cyst fluid samples were obtained postoperatively from surgically resected specimens. Although, essential differences may not exist between different approaches to obtaining cyst fluid samples, it is crucial to validate our results in endoscopically obtained specimens preoperatively to ensure their clinical application and guide surgical decision-making effectively.

In summary, the present study identified N-glycosylated PHKB (Asn-935, H5N2F0S0; Asn-935, H4N4F0S0; Asn-935, H5N4F0S0), CEACAM5 (Asn-197, H5N4F0S0) and ATP6V0A4 (Asn-367, H6N4F0S0) as promising cyst fluid biomarkers that exhibited high accuracy and outperformed traditional protein biomarkers in distinguishing malignant PCNs. These timely findings present potential clinical implications for PCN decision-making.

Materials and methods

Sample collection

Pancreatic cyst fluid samples were prospectively collected according to the approved protocols by the medical ethics committee at Peking Union Medical College Hospital (JS-1893). All enrolled patients underwent surgical resection, during which pancreatic cysts were removed, and cyst fluid samples were aspirated. These samples were then stored at −80 °C. The diagnosis was established through pathological examination and reviewed by experienced pathologists with a subspecialty in gastrointestinal pathology. Written informed consent was obtained from all patients.

Sample preparation

Briefly, proteins present in the cyst fluid were precipitated by acetone and resuspended in RIPA work solution (Sangon Biotech). After centrifugation, the supernatants containing the extracted proteins were obtained, and protein concentrations were assessed utilizing the BCA assay (Beyotime). Equal amounts of cyst fluid protein solutions from each sample were taken for subsequent glycoproteomic (1 mg per sample) and proteomic (50 μg per sample) analysis. Proteins underwent reduction with dithiothreitol, followed by alkylation with iodoacetamide, and subsequently digested with trypsin (Promega) overnight. The digested samples were subsequently acidified with trifluoroacetic acid, desalted with C18 solid phase extraction columns, and concentrated to dryness using a Speed-Vac. For glycoproteomic analysis, the intact N-glycopeptides were additionally enriched through ZIC-HILIC (Merck Millipore, 5 μm, 200Å) and concentrated to dryness using Speed-Vac.

LC-MS/MS for N-glycoproteomic analysis

N-glycopeptide samples were trapped and subsequently separated using a two-column setup as previously described, all within an Ultimate 3000 RSLCnano system (Thermo Fisher Scientific).³⁴ The mobile phase utilized an acetonitrile (ACN) - H₂O- formic acid (FA) system. Buffer A consisted of H₂O with 0.1% FA, while buffer B comprised 99.9% ACN with 0.1% FA. A stepwise gradient was employed: an initial 2% buffer B for 12 min, followed by a progression from 2 to 40% buffer B for 188 min, then a transition from 40 to 95% buffer B for 10 min, maintaining 95% buffer B for 5 min, a return from 95 to 2% buffer B for 5 min, and finally a retention at 2% buffer B for the last 20 min. MS spectra were acquired on an Orbitrap Exploris 480 (Thermo Fisher Scientific) with the following settings: a mass-to-charge ratio (m/z) range of 700–2000, a mass resolution of 60,000 (at m/z 200), an automatic gain control (AGC) target value of 3 × 10⁶ with a maximum ion injection time of 20 ms. For MS/MS spectra acquisition, the instrument operated in top 20 data-dependent mode using these settings: a mass resolution of 30,000, an AGC target value of 5 × 10⁵ with a maximum ion injection time of 250 ms, and a dynamic exclusion of 20 sec.

LC-MS/MS for proteomic analysis

In the case of each sample, 2 μg of total peptides underwent separation and analysis utilizing an EASY-nLC 1200 system coupled to a Q Exactive HF-X mass spectrometer (Thermo Fisher Scientific). A ReproSil C18 reversed-phase chromatographic column was used for separation. The mobile phase utilized an ACN- H₂O-FA system. Buffer A consisted of H₂O with 0.1% FA and 2% ACN. Buffer B comprised 80% ACN with 0.1% FA. After equilibrating the chromatographic column with 100% buffer A, the samples were loaded directly onto the column and subsequently underwent separation through a 120-minute gradient. A stepwise gradient was utilized. The MS1 scan covered an m/z range of 350 - 1600 with a resolution of 120,000 (at 200 m/z), an AGC target value of 3 × 10⁶, and a maximum ion injection time of 50 ms. The top 20 ions in the MS1 scan were subjected to quadrupole selection and then fragmented using HCD for the MS2 scan. The resolution was configured at 15,000 for MS2. The AGC target value was set to 1 × 10⁵ for MS2 with a maximum ion injection time of 110 ms. A dynamic exclusion time of 45 sec was implemented based on chromatographic peak width. Peaks with a single charge and those with charges surpassing 6 were excluded from the MS2 scan.

Identification and quantification of N-glycoproteins

Raw MS files were processed and searched using GPSeeker based on UniProt databases and homemade intact N-glycopeptide databases.¹⁹ Carbamidomethyl was designated as fixed modifications, and N-glycosylation was designated as variable modifications. A maximum of one trypsin missed-cleavage site was allowed. The glycopeptide spectrum matches underwent screening based on the following criteria: a GF score of at least 2, a Gly-bracket count of at least 1, considering the top 4 Y1 ions, ensuring a minimum of 10% matched fragment ions, requiring at least 1 matched product ion for every N-glycan moiety, and selecting the Top2 hits (where Top1 hits have the lowest P-score). For each intact N-glycopeptide ID, GPSeeker was employed to search for its precursor ion abundance, and label-free quantitation was performed. Relative quantitation was achieved by utilizing the cumulative abundance of the Top 3 isotopic peaks for each precursor ion.

Identification and quantification of global proteins

The Proteome Discoverer software (Version 2.4.0.305) was employed to process the raw MS files, and the included Sequest HT search engine was used for the search. The MS spectra were matched against the UniProt human databases. Carbamidomethyl (C) was designated as fixed modifications, and oxidation (M) and acetyl (Protein N-term) were designated as variable modifications. A maximum of two trypsin missed-cleavage sites was allowed. Peptide identification entailed an initial precursor mass deviation allowance of no more than 10 ppm, along with a fragment mass deviation of 0.02 Da. Protein quantification relied on unique and Razor peptides. Normalization was conducted based on the total peptide amount.

PRM-based targeted glycoproteomic analysis

PRM detection was performed using the Q Exactive HF-X mass spectrometer (Thermo Fisher Scientific) with an orbitrap resolution of 15,000 (at 200 m/z) and an AGC target value of 1 × 10⁵. Skyline Software (Version 22.2) was used to analyze PRM-MS raw files by generating extracted ion chromatograms and performing peak integration. The summed peak area of nine most intense fragment ions was used to quantify glycopeptides.

Data analysis

Proteins and glycoproteins were quantified using label-free quantification intensity. Missing values in the raw data were implemented with half of the minimum value. For proteomic analysis, an experimental/control fold change of greater than 1.2 or less than 0.83 as well as p < 0.05 was defined as differentially expressed. For glycoproteomic analysis, intact N-glycopeptide IDs with an experimental/control fold change of greater than 1.5 or less than 0.67 as well as p < 0.05 were classified as differentially expressed intact N-glycopeptides. P values were derived using two-tailed t test or chi-square test, as appropriate. For the t test, the Welch correction was applied for unequal variances. Proteins or glycoproteins detected in less than three of all samples were excluded from the results. Bioinformatics was performed by R software (version 3.6.1) and Python software (version 3.9.7).

Data availability

All data that support the findings of this study are available from the corresponding author upon reasonable request.

References

van, Huijgevoort, N., Chiaro, M.D., Wolfgang, C. L., van Hooft, J. E. & Besselink, M. G. Diagnosis and management of pancreatic cystic neoplasms: current evidence and guidelines. Nat. Rev. Gastroenterol. Hepatol. 16, 676–689 (2019).
Article PubMed Google Scholar
Kromrey, M. et al. Prospective study on the incidence, prevalence and 5-year pancreatic-related mortality of pancreatic cysts in a population-based study. Gut 67, 138–145 (2017).
Article PubMed Google Scholar
Søreide, K. & Marchegiani, G. Clinical management of pancreatic premalignant lesions. Gastroenterology. 162, 379–384 (2022).
Article PubMed Google Scholar
Aleotti, F. et al. Pancreatic resections for benign intraductal papillary mucinous neoplasms: collateral damages from friendly fire. Surgery 172, 1202–1209 (2022).
Article PubMed Google Scholar
Singhi, A. D., Koay, E. J., Chari, S. T. & Maitra, A. Early detection of pancreatic cancer: opportunities and challenges. Gastroenterology 156, 2024–2040 (2019).
Article PubMed Google Scholar
Tanaka, M. et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17, 738–753 (2017).
Article PubMed Google Scholar
European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut 67, 789–804 (2018).
Article Google Scholar
Elta, G. H., Enestvedt, B. K., Sauer, B. G. & Lennon, A. M. ACG clinical guideline: diagnosis and management of pancreatic cysts. Am. J. Gastroenterol. 113, 464–479 (2018).
Article PubMed Google Scholar
Pulvirenti, A. et al. Intraductal papillary mucinous neoplasms: have IAP consensus guidelines changed our approach? Ann. Surg. 274, e980–e987 (2021).
Article PubMed Google Scholar
Sharib, J. M. et al. Surgical overtreatment of pancreatic intraductal papillary mucinous neoplasms: do the 2017 International Consensus Guidelines improve clinical decision making? Surgery 164, 1178–1184 (2018).
Article PubMed Google Scholar
Chen, J. C., Beal, E. W., Pawlik, T. M., Cloyd, J. & Dillhoff, M. E. Molecular diagnosis of cystic neoplasms of the pancreas: a review. J. Gastrointest. Surg. 24, 1201–1214 (2020).
Article CAS PubMed Google Scholar
Cui, M. et al. A bibliometric study on pancreatic cystic disease research. J. Pancreatol. 2, 43–47 (2019).
Article Google Scholar
Paniccia, A. et al. Prospective, multi-institutional, real-time next-generation sequencing of pancreatic cyst fluid reveals diverse genomic alterations that improve the clinical management of pancreatic cysts. Gastroenterology. 164, 117–133 (2023).
Article CAS PubMed Google Scholar
Singhi, A. D. et al. Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia. Gut 67, 2131–2141 (2018).
Article CAS PubMed Google Scholar
Pinho, S. S. & Reis, C. A. Glycosylation in cancer: mechanisms and clinical implications. Nat. Rev. Cancer 15, 540–555 (2015).
Article CAS PubMed Google Scholar
Lumibao, J. C., Tremblay, J. R., Hsu, J. & Engle, D. D. Altered glycosylation in pancreatic cancer and beyond. J. Exp. Med. 219, e20211505 (2022).
Article CAS PubMed PubMed Central Google Scholar
Sun, S. et al. Comprehensive analysis of protein glycosylation by solid-phase extraction of N-linked glycans and glycosite-containing peptides. Nat. Biotechnol. 34, 84–88 (2016).
Article CAS PubMed Google Scholar
Pan, J. et al. Glycoproteomics-based signatures for tumor subty** and clinical outcome prediction of high-grade serous ovarian cancer. Nat. Commun. 11, 6139 (2020).
Article CAS PubMed PubMed Central Google Scholar
**ao, K. & Tian, Z. GPSeeker enables quantitative structural N‑glycoproteomics for site- and structure-specific characterization of differentially expressed N‑glycosylation in hepatocellular carcinoma. J. Proteome Res. 18, 2885–2895 (2019).
Article CAS PubMed Google Scholar
Kanda, Y. et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 17, 104–118 (2007).
Article CAS PubMed Google Scholar
Hu, Y. et al. Integrated proteomic and glycoproteomic characterization of human high-grade serous ovarian carcinoma. Cell Rep. 33, 108276 (2020).
Article CAS PubMed PubMed Central Google Scholar
Nista, E. C. et al. Humoral predictors of malignancy in IPMN: a review of the literature. Int. J. Mol. Sci. 22, 12839 (2021).
Article CAS PubMed PubMed Central Google Scholar
Maker, A. V. et al. Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. J. Am. Coll. Surg. 220, 243–253 (2015).
Article PubMed Google Scholar
Pflüger, M. J. et al. Predictive ability of pancreatic cyst fluid biomarkers: a systematic review and meta-analysis. Pancreatology. Publish Ahead of Print (2023).
Nikiforova, M. N. et al. A combined DNA/RNA-based next-generation sequencing platform to improve the classification of pancreatic cysts and early detection of pancreatic cancer arising from pancreatic cysts. Ann Surg. 278, e789–797 (2023).
Article PubMed Google Scholar
Xu, Y. et al. The next “sweet” spot for pancreatic ductal adenocarcinoma: glycoprotein for early detection. Mass Spectrom. Rev. 42, 822–843 (2023).
Article CAS PubMed Google Scholar
Beauchemin, N. & Arabzadeh, A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metast. Rev. 32, 643–671 (2013).
Article CAS Google Scholar
Faias, S., Cravo, M., Chaves, P. & Pereira, L. Comparative analysis of glucose and carcinoembryonic antigen in the diagnosis of pancreatic mucinous cysts: a systematic review and meta-analysis. Gastrointest. Endosc. 94, 235–247 (2021).
Article PubMed Google Scholar
Pont, L. et al. Site-specific N-linked glycosylation analysis of human carcinoembryonic antigen by sheathless capillary electrophoresis–tandem mass spectrometry. J. Proteome Res. 20, 1666–1675 (2021).
Article CAS PubMed PubMed Central Google Scholar
Zhao, Q. et al. Glycan analysis of colorectal cancer samples reveals stage-dependent changes in CEA glycosylation patterns. Clin. Proteom. 15, 9 (2018).
Article Google Scholar
Yang, W. et al. Phosphorylase kinase beta represents a novel prognostic biomarker and inhibits malignant phenotypes of liver cancer cell. Int. J. Biol. Sci. 15, 2596–2606 (2019).
Article CAS PubMed PubMed Central Google Scholar
Wang, G. et al. Phosphorylase kinase beta affects colorectal cancer cell growth and represents a novel prognostic biomarker. J. Cancer Res. Clin. Oncol. 143, 971–980 (2017).
Article CAS PubMed Google Scholar
Savci-Hei**k, C. D., Halfwerk, H., Koster, J., Horlings, H. M. & van de Vijver, M. J. A specific gene expression signature for visceral organ metastasis in breast cancer. BMC Cancer. 19, 333 (2019).
Article CAS PubMed PubMed Central Google Scholar
Lu, H., **ao, K. & Tian, Z. Benchmark of site- and structure-specific quantitative tissue N-glycoproteomics for discovery of potential N-glycoprotein markers: a case study of pancreatic cancer. Glycoconjugate J. 38, 213–231 (2021).
Article CAS Google Scholar

Download references

Acknowledgements

This work was supported by grants National Key R&D Program of China (No. 2020YFC2002702), National High Level Hospital Clinical Research Funding (2022-PUMCH-D-001), Bei**g Natural Science Foundation (No. 7224340), the Fundamental Research Funds for the Central Universities (No. 3332022006) and the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2018PT32014). The authors thank all patients for participating in this study. We would like to thank Lin Kang and Qiang Huang (Biotree Biotech, Shanghai, China) for their technical assistance.

Author information

These authors contributed equally: Ming Cui, Ya Hu

Authors and Affiliations

Department of General Surgery, Key Laboratory of Research in Pancreatic Tumor, State Key Laboratory of Complex Severe and Rare Disease, National Science and Technology Key Infrastructure on Translational Medicine in Peking Union Medical College Hospital, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Bei**g, 100730, China
Ming Cui, Ya Hu, Menghua Dai, Qiang Xu, Junchao Guo, Tai** Zhang, Quan Liao & Yupei Zhao
Department of Medical Research Center, State Key Laboratory of Complex Severe and Rare Disease, National Science and Technology Key Infrastructure on Translational Medicine in Peking Union Medical College Hospital, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Bei**g, 100730, China
Zejian Zhang & Tianqi Chen
Department of Medicine, Oncology, and Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA
Jun Yu
Pancreas center, Tian** Medical University Cancer Institute and Hospital, Tian**, 300060, China
Jun Yu

Authors

Ming Cui
View author publications
You can also search for this author in PubMed Google Scholar
Ya Hu
View author publications
You can also search for this author in PubMed Google Scholar
Zejian Zhang
View author publications
You can also search for this author in PubMed Google Scholar
Tianqi Chen
View author publications
You can also search for this author in PubMed Google Scholar
Menghua Dai
View author publications
You can also search for this author in PubMed Google Scholar
Qiang Xu
View author publications
You can also search for this author in PubMed Google Scholar
Junchao Guo
View author publications
You can also search for this author in PubMed Google Scholar
Tai** Zhang
View author publications
You can also search for this author in PubMed Google Scholar
Quan Liao
View author publications
You can also search for this author in PubMed Google Scholar
Jun Yu
View author publications
You can also search for this author in PubMed Google Scholar
Yupei Zhao
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

M.C., Y.H., J.Y., and Y.Z. contributed to the conception. M.C., Z.Z., and T.C. performed the experiments. M.D., Q.X., J.G., T.Z., Q.L., and Y.Z. enrolled patients and collected samples. M.C., Y.H., and J.Y. wrote the original draft. All the authors have reviewed and approved the final manuscript.

Corresponding author

Correspondence to Yupei Zhao.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethical approval

The study complied with the Declaration of Helsinki and was approved by the medical ethics committee at Peking Union Medical College Hospital (JS-1893, ZX002).

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Cui, M., Hu, Y., Zhang, Z. et al. Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm. Sig Transduct Target Ther 8, 406 (2023). https://doi.org/10.1038/s41392-023-01645-8

Download citation

Received: 28 December 2022
Revised: 26 June 2023
Accepted: 13 September 2023
Published: 18 October 2023
DOI: https://doi.org/10.1038/s41392-023-01645-8
Springer Nature Limited

Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm

Abstract

Similar content being viewed by others

Quantitative proteomic analysis of pancreatic cyst fluid proteins associated with malignancy in intraductal papillary mucinous neoplasms

Integrated targeted metabolomic and lipidomic analysis: A novel approach to classifying early cystic precursors to invasive pancreatic cancer

Molecular Diagnosis of Cystic Neoplasms of the Pancreas: a Review

Introduction

Identification of potential cyst fluid glycoproteins as novel biomarkers in distinguishing malignant PCNs

Validation of cyst fluid glycoprotein biomarkers in distinguishing malignant PCNs

Discussion

Materials and methods

Sample collection

Sample preparation

LC-MS/MS for N-glycoproteomic analysis

LC-MS/MS for proteomic analysis

Identification and quantification of N-glycoproteins

Identification and quantification of global proteins

PRM-based targeted glycoproteomic analysis

Data analysis

Data availability

References

Acknowledgements

Author information

Authors and Affiliations

Contributions

Corresponding author

Ethics declarations

Competing interests

Ethical approval

Rights and permissions

About this article

Cite this article

Navigation

Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm

Abstract

Similar content being viewed by others

Quantitative proteomic analysis of pancreatic cyst fluid proteins associated with malignancy in intraductal papillary mucinous neoplasms

Integrated targeted metabolomic and lipidomic analysis: A novel approach to classifying early cystic precursors to invasive pancreatic cancer

Molecular Diagnosis of Cystic Neoplasms of the Pancreas: a Review

Introduction

Identification of potential cyst fluid glycoproteins as novel biomarkers in distinguishing malignant PCNs

Validation of cyst fluid glycoprotein biomarkers in distinguishing malignant PCNs

Discussion

Materials and methods

Sample collection

Sample preparation

LC-MS/MS for N-glycoproteomic analysis

LC-MS/MS for proteomic analysis

Identification and quantification of N-glycoproteins

Identification and quantification of global proteins

PRM-based targeted glycoproteomic analysis

Data analysis

Data availability

References

Acknowledgements

Author information

Authors and Affiliations

Contributions

Corresponding author

Ethics declarations

Competing interests

Ethical approval

Rights and permissions

About this article

Cite this article

Share this article

Search

Navigation